These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39052257)

  • 21. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
    BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Unselected Multigene Germline and Somatic Genetic Testing for Epithelial Ovarian Cancer.
    Manchanda R; Sun L; Sobocan M; Rodriguez IV; Wei X; Kalra A; Oxley S; Sideris M; Fierheller CT; Morgan RD; Chandrasekaran D; Rust K; Spiliopoulou P; Miller RE; Crusz SM; Lockley M; Singh N; Faruqi A; Casey L; Brockbank E; Phadnis S; Mills-Baldock T; El-Khouly F; Jenkins LA; Wallace A; Ahmed M; Kumar A; Swisher EM; Gourley C; Norquist BM; Evans DG; Legood R
    J Natl Compr Canc Netw; 2024 Apr; 22(2 D):. PubMed ID: 38866043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
    Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
    Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
    Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
    BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
    Apostolou P; Fostira F; Kouroussis C; Kalfakakou D; Delimitsou A; Agelaki S; Androulakis N; Christodoulou C; Kalbakis K; Kalykaki A; Sanidas E; Papadimitriou C; Vamvakas L; Georgoulias V; Mavroudis D; Yannoukakos D; Konstantopoulou I; Saloustros E
    Int J Cancer; 2020 Sep; 147(5):1334-1342. PubMed ID: 32022259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases.
    Faria JP; Assumpção JG; de Oliveira Matos L; Soardi FC; Bretz GPM; Friedman E; De Marco L
    Breast Cancer Res Treat; 2024 Oct; 207(3):615-624. PubMed ID: 38874686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
    Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
    Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with
    Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L
    Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population.
    Li D; Shi Y; Li A; Cao D; Su H; Yang H; Zhi Q; Yang Y; Lan Z; Zhou T; You X; Hu G
    Breast Cancer; 2020 Nov; 27(6):1158-1167. PubMed ID: 32566972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline mutational variants of Turkish ovarian cancer patients suspected of Hereditary Breast and Ovarian Cancer (HBOC) by next-generation sequencing.
    Tuncer SB; Celik B; Erciyas SK; Erdogan OS; Gültaslar BK; Odemis DA; Avsar M; Sen F; Saip PM; Yazici H
    Pathol Res Pract; 2024 Feb; 254():155075. PubMed ID: 38219492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype.
    Zang F; Ding X; Chen J; Hu L; Sun J; Zhang J; Xu Y; Yao L; Xie Y
    Breast Cancer Res Treat; 2022 Oct; 195(3):431-439. PubMed ID: 35974241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of germline pathogenic
    Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
    J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.
    Kast K; Rhiem K; Wappenschmidt B; Hahnen E; Hauke J; Bluemcke B; Zarghooni V; Herold N; Ditsch N; Kiechle M; Braun M; Fischer C; Dikow N; Schott S; Rahner N; Niederacher D; Fehm T; Gehrig A; Mueller-Reible C; Arnold N; Maass N; Borck G; de Gregorio N; Scholz C; Auber B; Varon-Manteeva R; Speiser D; Horvath J; Lichey N; Wimberger P; Stark S; Faust U; Weber BH; Emons G; Zachariae S; Meindl A; Schmutzler RK; Engel C;
    J Med Genet; 2016 Jul; 53(7):465-71. PubMed ID: 26928436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis.
    Witjes VM; van Bommel MHD; Ligtenberg MJL; Vos JR; Mourits MJE; Ausems MGEM; de Hullu JA; Bosse T; Hoogerbrugge N
    Gynecol Oncol; 2022 Jan; 164(1):221-230. PubMed ID: 34702566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers.
    Laitman Y; Keinan Boker L; Liphsitz I; Weissglas-Volkov D; Litz-Philipsborn S; Schayek H; Friedman E
    Breast Cancer Res Treat; 2015 Apr; 150(3):631-5. PubMed ID: 25788227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
    Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Lee A; Moon BI; Kim TH
    Ann Lab Med; 2020 Mar; 40(2):114-121. PubMed ID: 31650727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathologic features and genetic characteristics of the BRCA1/2 mutation in Turkish breast cancer patients.
    Cecener G; Sabour Takanlou L; Sabour Takanlou M; Egeli U; Eskiler GG; Aksoy S; Unal U; Tezcan H; Eryilmaz IE; Gokgoz MS; Tunca B; Cubukcu E; Evrensel T; Cetintas S; Tasdelen I
    Cancer Genet; 2020 Jan; 240():23-32. PubMed ID: 31706072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double heterozygotes of BRCA1/BRCA2 and mismatch repair gene pathogenic variants: case series and clinical implications.
    Laish I; Friedman E; Levi-Reznick G; Kedar I; Katz L; Levi Z; Halpern N; Parnasa S; Abu-Shatya A; Half E; Goldberg Y
    Breast Cancer Res Treat; 2021 Aug; 188(3):685-694. PubMed ID: 34086170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.